{"publication_id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","content_hash":"sha256:620863b04e6e871c8f4835c6ed3473c871a033ea7628b48fbfbd81ddc430650a","nodes":[{"id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","type":"publication","title":"Bounded Subcutaneous semaglutide signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; patients with overweight or obesity without diabetes mellitus; patients with type 2 diabetes and established CV disease or CV risk factors. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim."},{"id":"claim_4","type":"claim","text":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._"},{"id":"claim_5","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_6","type":"claim","text":"`fact_id=137451` (`A_core`) — Compared with placebo, the use of semaglutide was associated with substantial decreases in long-term relative (WMD -12.1%, 95% CI -13.5 to -10.7) and absolute body weight doi=10.1016/j.amjcard.2024.04.041"},{"id":"claim_7","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_8","type":"claim","text":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._"},{"id":"source_1","type":"source","study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","year":2024,"doi":"10.1111/obr.13792","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","year":2021,"doi":"10.3389/fendo.2021.645566","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"doi":"10.1016/j.amjcard.2024.04.041","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_1","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_2","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_3","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_4","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_5","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_6","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_7","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_8","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}